Tirzepatide (5mg)
Best recently released GLP-1 med
600.000 ₫
Tirzepatide is a dual GLP-1 / GIP receptor agonist developed by Eli Lilly. The dual-receptor mechanism produces stronger weight-loss and glucose effects than first-generation GLP-1-only agonists like semaglutide. In the SURMOUNT-1 trial, weekly Tirzepatide produced 20.9% mean weight loss at 72 weeks at the 15mg dose — substantially higher than the 14.9% seen with semaglutide in STEP-1 — with reductions in HbA1c, blood pressure, liver fat and inflammatory markers. GI side effects (nausea, transient) are dose-related and manageable via slow titration. Subcutaneous weekly dosing, titrated upward over 4–8 weeks. The current standard-of-care choice when the goal is large, durable weight loss with a strong evidence base.
Dosage
Start 2.5mg once weekly; double to 5mg after 4 weeks, then step up every 4 weeks (SURMOUNT titration)
Key Features
- Most effective weight loss
- Dual-action mechanism
- Improved glycemic control
- Appetite suppression
Includes key details, half-life data, usage notes and research sources.
Dose Titration Schedule
Gradual dose escalation minimizes side effects. Administered once weekly via subcutaneous injection.
Weeks 1–4
Starting dose — assess tolerability
Weeks 5–8
First increase — standard maintenance
Weeks 9–12
Intermediate step if needed
Weeks 13–16
Higher maintenance dose
Weeks 17+
Maximum therapeutic dose
Important Notes
- • Dose increases should only occur every 4 weeks
- • Only increase if current dose is well tolerated
- • Consult your healthcare provider before adjusting dose
Usage Instructions
Subcutaneous injection once weekly. Start with the lowest dose and titrate up as directed by your healthcare provider. Store refrigerated.
Research Highlights
- Clinical trials demonstrate significant weight reduction
- Improved glycemic control and insulin sensitivity
- Long-term studies show sustained weight maintenance
Safety Information
- •Thyroid tumors: Tirzepatide caused thyroid C-cell tumours in rodents. Whether it does so in humans is unknown. The branded medicine must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
- •Pancreatitis: Pancreatitis has been reported in clinical trials. Stop and seek medical attention if severe, persistent abdominal pain occurs.
- •Gallbladder disease: Gallbladder problems, including gallstones, have been reported, especially with rapid weight loss.
- •Kidney problems: Vomiting and diarrhoea can cause dehydration, which can lead to acute kidney injury. Drink enough fluids.
Human Clinical Trials
- SURMOUNT-1New England Journal of Medicine · 2022
72-week obesity trial: 20.9% weight loss on 15mg tirzepatide versus 3.1% on placebo.
Read the trial2539participants - SURMOUNT-OSANew England Journal of Medicine · 2024
Obstructive sleep apnoea: breathing interruptions fell by 25.3 per hour on tirzepatide versus 5.3 on placebo.
Read the trial469participants - SUMMITNew England Journal of Medicine · 2024
Heart failure with preserved ejection fraction and obesity: 9.9% of tirzepatide patients had a cardiovascular death or worsening event versus 15.3% on placebo.
Read the trial731participants - SURPASS-1The Lancet · 2021
Type 2 diabetes monotherapy: HbA1c fell by up to 2.07 percentage points versus placebo.
Read the trial478participants - SURPASS-5JAMA · 2022
Added to insulin glargine, tirzepatide lowered HbA1c and body weight significantly more than placebo.
Read the trial475participants - SURPASS-CVOTNew England Journal of Medicine · 2025
Long-term cardiovascular outcomes in type 2 diabetes, comparing tirzepatide with dulaglutide.
Compared against another active drug, not placebo.
Read the trial13299participants